

# HUMAN PAPILOMAVIRUS (HPV) VACCINE IMPACT AND ALASKA RESEARCH

---

MCH – Immunization Conference  
September 24, 2014

**Thomas Hennessy MD**

Arctic Investigations Program – CDC

**Rosalyn Singleton MD**

State of Alaska – Epidemiology; ANTHC

**Jamie Blei**

Alaska Center for Pediatrics- Care Coordinator

# Why vaccinate at age 11-12 years?

*"Timing of HPV vaccine Jonathan L. Temte, Chair, US Advisory Committee on Immunization Practices  
University of Wisconsin School of Medicine and Public Health*

*Timing of HPV vaccination is of critical importance to the success of this vaccine. HPV discussion at younger ages often collides with the clinician's angst in discussing sex in early adolescence....I have found a simple analogy of great utility... When discussing HPV vaccine with 11 and 12 year-olds and their parents, I will ask the simple question:*

*When do you want your children to put on their bike helmets?*


- A. Before they get on their bike*
- B. When they are riding their bike in the street*
- C. When they see the car heading directly at them*
- D. After the car hits them*

*I usually end up with a smile and a successfully launched series.*

The work of Perkins, et al. [2] validates the difficulties incurred with provider hesitancy. Reassurance on the long-term effectiveness of HPV vaccine, as shown by Ferris and colleagues [3], removes another of the buttresses of this hesitancy.


1. Offit PA. Let's Not Talk About Sex. New York Times Opinion, Aug 19.2014.
2. Perkins RB, Clark JA, Apte G, et al. Missed opportunities for HPV vaccination in adolescent girls Pediatrics 2014;134:e666-674.
3. Ferris D, Samakoses R, Block SL, et al. Long-term study of quadrivalent human papillomavirus vaccine. Pediatrics 2014;134:e557-665.

# Estimated Vaccination Coverage Levels among Adolescents 13-17 Years, United States 2006-2012



# HPV coverage in adolescent girls 13-17 years, 2007-2013

## Are we doing better in 2013?



Vaccination coverage significantly increased in 2013; 57.3% of girls and 34.6% of boys received  $\geq 1$  dose of HPV vaccine.

<http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6329a3.htm>

# INITIAL HIGH HPV VACCINE UPTAKE AMONG ALASKA NATIVE TEENS 2007-2010

Tania Smallenberg RN, Rosalyn Singleton MD, Gina Carpenter RN,  
Kathleen Stanton RN, Melissa Kemberling PhD

- Alaska Native-specific brochure, poster, and story videos were developed and distributed to over 250 tribal clinics and hospitals.
  - HPV information was presented to health care personnel and tribal leaders at grand rounds, conferences and tribal board meetings.
- 
- The vaccine was provided by the State Immunization Program in June 2007.
  - All tribal facility clinics and public health nursing offered HPV vaccine.
  - Vaccine coverage rates were evaluated through computer-based records system for 13-17 year old girls who had 2 visits within 3 years at a tribal facility.

**Results:** Vaccination rates for  $\geq 1$  dose of HPV among Alaska Native teen girls aged 13-17 years increased from 26% on 3/31/08 to 61% on 12/31/08 to 71% on 9/30/09 while vaccination rates for 3 doses of HPV increased from 2% to 15% to 32% in the same time period.


# Patient Education: Poster, Brochures, Story Videos



- Initial education efforts included a poster and brochure focusing on multi-generational family involvement in decision-making
- Additional educational booklets were focused on older teens and young adults
- Story videos were also developed by Alaska Native teens and placed on Facebook


# Results:

HPV coverage rates for Alaska Native 13-17 year olds, 2007-2009



# Results:

HPV coverage for U.S. (NIS 2008) vs. Alaska Natives (12/31/2008)







# EAT Teen male HPV4 Coverage – March 2014

## Parent Reminders Make an Impact

Eastern Aleutian Tribes sends HPV vaccine reminder letters along with information about human papillomavirus. This region's HPV vaccine completion rates among males is well above our aggregate rates.



# Top 5 reasons for not vaccinating daughter, among parents with no intention to vaccinate in the next 12 months, NIS-Teen 2012



\* Not mutually exclusive.

\*\* Did not know much about HPV or HPV vaccine.

# Recommendations based on Research with Moms

- Focus communication messages for parents
  - HPV Vaccine is Cancer Prevention
  - Describe types of cancers prevented
  - Importance of vaccination at 11 or 12
  - More information about side effects
  - Name credible organizations that support HPV vaccine recommendation
- Layer messages to allow parents to easily choose the level of detail they wish to pursue

# Goals Based on Formative Research

## WE WANT PARENTS TO:

- Realize HPV vaccine is CANCER PREVENTION
- Understand HPV vaccine is best at 11 or 12 years old
- Recognize importance of getting all 3 shots

## WE WANT HEALTHCARE

## PROFESSIONALS TO:

- Be familiar with all of the indications for HPV vaccine
- Make strong recommendations for receiving vaccine at 11 or 12
- Be aware of, and interested in, systems that can improve practice vaccination rates

# Primary Care Process Improvement

## Role of Providers

- Change in Dialogue
- Parent Education
- Appointment Process

## Clinical Staff

- Recall Input
- Communication with Family
- Review of Appointments Scheduled


## Support Staff

- HPV Doses #2 and #3 Scheduled
- Reminder and Confirmation Call
- Action for Missed Appointments



# HPV Reminder Magnets

- May 19, 2014 thru September 1, 2014
- Date of Dose #1 Documented
- Magnet Activated
- Appointments Added for Dose #2 and #3
- 95% Dose #2 Completion Rate by September 1st



**GARDASIL.**  
[Human Papillomavirus Quadrivalent  
(Types 6, 11, 16, and 18) Vaccine, Recombinant]

	DATE	
<b>1<sup>st</sup></b>	Appt. _____ TODAY	<input type="checkbox"/>
<b>2<sup>nd</sup></b>	Appt. _____ AT 2 MONTHS	<input type="checkbox"/>
<b>3<sup>rd</sup></b>	Appt. _____ AT 6 MONTHS	<input checked="" type="checkbox"/>

If you miss an appointment, please contact your health care professional to determine when your next appointment should be.

**MERCK** VACC-1056727-0001 12/12  
Copyright © 2012 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. All rights reserved.